SecurityADBE / Adobe Systems, Inc. (00724F101)
IndustryPrepackaged Software
Common Stock Shares Outstanding492,880,000 shares (as of 2018-03-02)
Total Insiders31
Total Directors17
Total Officers12

Stock Insider Trading (from SEC Form 4)

Adobe Systems, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ADBE / Adobe Systems, Inc. insiders include ValueAct Capital Management, LLC, WARNOCK JOHN E, GARRETT MARK, GESCHKE CHARLES M, VA Partners I, LLC, DALEY JAMES E, Belsky Scott, and ValueAct Holdings GP, LLC, Banse Amy, LAMKIN BRYAN, Morris Donna, Rencher Bradley, Ricks David A NARAYEN SHANTANU, DILLON MICHAEL A, Murphy John Francis, Parasnis Abhay, Desmond Laura, BARNHOLT EDWARD W, ValueAct Holdings, L.P., ValueAct Capital Master Fund, L.P., CANNON MICHAEL R, SEDGEWICK ROBERT, BURGESS ROBERT K, ValueAct Capital Management, L.P., CALDERONI FRANK, ROSENSWEIG DANIEL, Barlow Kelly J, ROWLEY RICHARD, THOMPSON MATTHEW, Lewnes Ann, .

Insider Roster

Insider Dir Off 10% Shares Owned
Lewnes Ann EVP, Chief Marketing Officer
X 70,322
GESCHKE CHARLES M Director
X 158,059
Banse Amy Director
X 33,488
Ricks David A Director
X 0
CALDERONI FRANK Director
X 25,887
BURGESS ROBERT K Director
X 16,030
BARNHOLT EDWARD W Director
X 42,960
ROSENSWEIG DANIEL Director
X 13,104
WARNOCK JOHN E Director
X 470,344
Desmond Laura Director
X 25,887
DALEY JAMES E Director
X 32,922
Murphy John Francis EVP and CFO
X
DILLON MICHAEL A EVP, Gen. Counsel & Secretary
X 50,614
GARRETT MARK EVP, CFO & Asst. Secretary
X 50,000
LAMKIN BRYAN EVP & GM, Digital Media
X 60,154
THOMPSON MATTHEW EVP WW Field Operations
X 50,000
Rencher Bradley EVP & GM, Experience Cloud
X 94,830
Parasnis Abhay EVP & CTO
X 20,685
Morris Donna EVP, Cust. & Emp. Experience
X 65,083
Belsky Scott EVP, Chief Product Officer
X
NARAYEN SHANTANU Chairman, President and CEO, Director
X X 299,514
ROWLEY RICHARD VP, Corp. Controller & CAO
X
ValueAct Holdings, L.P. Director
ValueAct Holdings GP, LLC Director
ValueAct Capital Management, LLC Director
ValueAct Capital Management, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Master Fund, L.P. Director
Barlow Kelly J Director
X
SEDGEWICK ROBERT Director
X
CANNON MICHAEL R Director
X
ValueAct Capital Master Fund, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Management, L.P. Director
ValueAct Capital Management, LLC Director
ValueAct Holdings GP, LLC Director
ValueAct Holdings, L.P. Director
X
ValueAct Capital Management, L.P. Director
ValueAct Holdings GP, LLC Director
ValueAct Capital Management, LLC Director
ValueAct Holdings, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Master Fund, L.P. Director
X
ValueAct Holdings GP, LLC Director
ValueAct Capital Management, LLC Director
ValueAct Capital Management, L.P. Director
VA Partners I, LLC Director
ValueAct Capital Master Fund, L.P. Director
ValueAct Holdings, L.P. Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-16 4 Lewnes Ann S X D 236.59 -2,942 70,322 16,637,482
2018-04-20 4 GESCHKE CHARLES M By Family Trust S I 225.0844 -6,000 158,059 35,576,615
2018-04-20 4 GESCHKE CHARLES M By Family Trust S I 223.9118 -10,000 164,059 36,734,746
2018-04-18 4 Lewnes Ann S X D 231.70 -2,937 73,264 16,975,269
2018-04-11 4 DALEY JAMES E M D 2,035 32,922
2018-04-11 4 Desmond Laura M D 2,035 25,887
2018-04-11 4 GESCHKE CHARLES M By Family Trust M I 2,035 174,059
2018-04-11 4 WARNOCK JOHN E by trust S I 223.7721 -3,000 470,344 105,249,865
2018-04-11 4 WARNOCK JOHN E by trust M I 2,035 473,344
2018-04-11 4 ROSENSWEIG DANIEL M D 2,035 13,104
2018-04-11 4 BARNHOLT EDWARD W M D 2,035 42,960
2018-04-11 4 BURGESS ROBERT K by trust M I 2,035 16,030
2018-04-11 4 CALDERONI FRANK M D 2,035 25,887
2018-04-11 4 Banse Amy M D 2,035 33,488
2018-03-29 4 WARNOCK JOHN E by trust S I 218.0016 -5,000 471,309 102,746,116
2018-03-29 4 WARNOCK JOHN E by trust S I 216.0592 -6,000 476,309 102,910,941
2018-03-29 4 WARNOCK JOHN E by trust S I 215 -3,000 482,309 103,696,435
2018-03-22 4 Lewnes Ann S X D 223.86 -2,940 76,201 17,058,356
2018-03-20 4 Murphy John Francis F D 229.75 -2,288 3,555
2018-03-20 4 Murphy John Francis M D 5,750 5,843
2018-03-20 4 WARNOCK JOHN E by trust S I 229.5594 -2,500 485,309 111,407,243
2018-03-19 4 WARNOCK JOHN E by trust S I 220.3298 -2,500 487,809 107,478,859
2018-02-06 4 GARRETT MARK S X D 188.2518 -16,720 50,000 9,412,590
2018-02-06 4 GARRETT MARK S X D 187.988 -24,468 66,720 12,542,559
2018-02-06 4 GARRETT MARK S X D 186.5531 -3,900 91,188 17,011,404
2018-02-06 4 GARRETT MARK S X D 185.6946 -2,280 95,088 17,657,328
2018-02-06 4 GARRETT MARK S X D 184.2585 -7,120 97,368 17,940,882
2018-02-05 4 DILLON MICHAEL A S X D 194.8574 -7,400 50,614 9,862,512
2018-02-05 4 DILLON MICHAEL A S X D 194.2168 -5,958 58,014 11,267,293
2018-02-05 4 DILLON MICHAEL A S X D 193.3675 -4,721 63,972 12,370,106
2018-01-31 4 DILLON MICHAEL A S X D 197.13 -6,376 68,693 13,541,451
2018-01-31 4 LAMKIN BRYAN S D 199.0785 -30,000 60,154 11,975,368
2018-01-26 4 THOMPSON MATTHEW Trust S I 200.0765 -50,775 50,000 10,003,825
2018-01-25 4 NARAYEN SHANTANU by trust S I 198.6211 -57,352 299,514 59,489,800
2018-01-25 4 NARAYEN SHANTANU by trust S I 197.6312 -92,539 356,866 70,527,856
2018-01-25 4 NARAYEN SHANTANU by trust S I 196.7502 -15,132 449,405 88,420,524
2018-01-24 4 NARAYEN SHANTANU by trust F I 197.78 -14,044 464,537
2018-01-24 4 NARAYEN SHANTANU by trust M I 28,327 478,581
2018-01-24 4 NARAYEN SHANTANU by trust F I 197.78 -16,190 450,254
2018-01-24 4 NARAYEN SHANTANU by trust M I 32,655 466,444
2018-01-24 4 NARAYEN SHANTANU by trust F I 197.78 -18,757 433,789
2018-01-24 4 NARAYEN SHANTANU by trust M I 37,833 452,546
2018-01-24 4 NARAYEN SHANTANU by trust F I 197.78 -111,801 414,713
2018-01-24 4 NARAYEN SHANTANU by trust M I 227,000 526,514
2018-01-24 4 DILLON MICHAEL A F D 197.78 -3,121 75,069
2018-01-24 4 DILLON MICHAEL A M D 6,295 78,190
2018-01-24 4 DILLON MICHAEL A F D 197.78 -3,148 71,895
2018-01-24 4 DILLON MICHAEL A M D 6,350 75,043
2018-01-24 4 DILLON MICHAEL A F D 197.78 -2,842 68,693
2018-01-24 4 DILLON MICHAEL A M D 5,733 71,535
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Adobe Systems To Acquire Magento Commerce For Integrated Ecommerce

2018-05-23 seekingalpha
The deal is likely one of more to come for Adobe as it uses its balance sheet and recent stock price appreciation to expand its offerings. (58-0)

Adobe's New Buyback Program to Boost Shareholders' Confidence

2018-05-23 zacks
Adobe Systems (ADBE - Free Report) has announced a new share repurchase program. The company’s board of directors authorized buy back of shares worth up to $8 million. This will be executed through the fiscal year 2021 and funded from the future cash flow generation. The repurchases are likely to be made through both public market and structured share repurchase agreements with the third parties. The new share repurchase program is appreciably higher than its previous share repurchase authorization of up to $2. (62-0)

What Does Cap Ex Spending Tell Us About Oracle's Future Cloud Growth?

2018-05-23 seekingalpha
Oracle capital expenditures appear to be much lower than the rest of the major cloud providers. (200-0)

Even With Rising Bond Yields, Dividend Stocks Reign Supreme

2018-05-23 investorplace
Last week, income-oriented investors were dished out a surprise they had largely forgotten was even possible. That is, for the first time since 2008, short-term bond yields were greater than the payments being made by some of the market’s best-known dividend stocks. Specifically, the dividend yield for the S&P 500, as a whole, was surpassed by the yield of three-month Treasuries. (99-0)

Adobe Systems: Diverging Paths

2018-05-22 seekingalpha
The high-flying Adobe Systems (ADBE) made a couple of meaningful announcements after the market close on May 21. The market likes the moves though the headline grabbing buyback isn't that impressive or financially wise. The purchase of the commerce platform Magento is needed to drive the growth required to justify the stock valuation. (74-0)